Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
In Vitro Diagnostics

PUBLISHER: Grand View Research | PRODUCT CODE: 1678737

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1678737

Guillain-Barre Syndrome Diagnostics Market Size, Share & Trends Report By Test (Lumbar Puncture, Electromyography), By End-use (Hospitals And Clinics, Diagnostic Laboratories), By Region, And Segment Forecasts, 2025 - 2030

PUBLISHED:
PAGES: 150 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 5950
Printable PDF (5-User License)
USD 6950
Printable PDF (Enterprise License)
USD 8950

Add to Cart

Description

Table of Contents

List of Tables

Guillain-Barre Syndrome Diagnostics Market Growth & Trends:

The global guillain-barre syndrome diagnostics market size is expected to reach USD 169.9 million by 2030, registering a CAGR of 2.8% from 2025 to 2030, according to a new report by Grand View Research, Inc. driven by several key factors. A significant contributor is the increasing incidence of Guillain-Barre syndrome (GBS), particularly in regions with high rates of infectious diseases. Infections such as respiratory or gastrointestinal illnesses often precede GBS, leading to a heightened demand for effective diagnostic tools. For instance, a study from the University of Minnesota in October 2023 highlighted that 67% of GBS cases were preceded by such infections, underscoring the need for timely diagnosis.

Advancements in diagnostic techniques have also played a crucial role in market expansion. Innovations in electromyography (EMG) and nerve conduction studies have enhanced the accuracy and speed of GBS diagnosis. These technological improvements enable healthcare professionals to detect the syndrome earlier, facilitating prompt intervention and better patient outcomes. The integration of advanced diagnostic tools in clinical settings has become increasingly prevalent, reflecting a commitment to improving patient care.

The growing awareness of GBS among healthcare providers and the general population has further propelled the diagnostics market. Educational initiatives and increased information dissemination have led to earlier recognition of symptoms and subsequent diagnostic testing. This heightened awareness ensures that patients receive timely and appropriate care, reducing the risk of severe complications associated with delayed diagnosis. Consequently, the demand for diagnostic services has risen, contributing to market growth.

The expanding geriatric population has influenced the market for GBS diagnostics. Older individuals are more susceptible to infections that can trigger GBS, necessitating effective diagnostic measures. According to the World Health Organization's 2021 forecast, by 2030, one in six individuals worldwide will be over 60, with their numbers expected to grow from 1 billion in 2020 to 2.1 billion by 2050. This demographic shift underscores the importance of accessible and accurate diagnostic tools to manage the anticipated increase in GBS cases among the elderly.

Key players in the market are implementing strategic initiatives such as geographical expansion, collaborations, partnerships, and joint ventures to strengthen their market presence.

Guillain-Barre Syndrome Diagnostics Market Report Highlights:

  • The test segment of the market includes lumbar puncture, electromyography, nerve conduction studies, and others. The lumbar puncture segment led the market in 2024, accounting for the largest revenue share of 45.1%, and is expected to experience the fastest compound annual growth rate (CAGR) of 3.0% during the forecast period, driven by its essential role in confirming GBS diagnosis.
  • The end-use segment comprises hospitals & clinics, and diagnostic laboratories. In 2024, the hospitals & clinics segment led the market, capturing a revenue share of 63.0%, driving significant growth through the integration of advanced diagnostic tools and improved patient management protocols.
  • Asia Pacific dominated the global market with a revenue share of 41.8% in 2024. Factors such as rising awareness, improving healthcare infrastructure, and increasing diagnostic rates are driving market expansion.
Show more
Product Code: GVR-4-68040-522-7

Table of Contents

Chapter 1. Research Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Test
    • 1.1.2. End Use
    • 1.1.3. Regional scope
    • 1.1.4. Estimates and forecast timeline.
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database.
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
    • 1.6.2. Approach 1: Commodity flow approach
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Test outlook
    • 2.2.2. End use outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Guillain-Barre Syndrome (GBS) Diagnostics Market Variables, Trends & Scope

  • 3.1. Market Dynamics
    • 3.1.1. Market driver analysis
    • 3.1.2. Market restraint analysis
    • 3.1.3. Market opportunities analysis
  • 3.2. Guillain-Barre Syndrome (GBS) Diagnostics Market Analysis Tools
    • 3.2.1. Industry Analysis - Porter's
      • 3.2.1.1. Supplier power
      • 3.2.1.2. Buyer power
      • 3.2.1.3. Substitution threat
      • 3.2.1.4. Threat of new entrant
      • 3.2.1.5. Competitive rivalry
    • 3.2.2. PESTEL Analysis
      • 3.2.2.1. Political landscape
      • 3.2.2.2. Economic landscape
      • 3.2.2.3. Social landscape
      • 3.2.2.4. Technological landscape
      • 3.2.2.5. Environmental landscape
      • 3.2.2.6. Legal landscape
    • 3.2.3. COVID-19 Impact Analysis
    • 3.2.4. Case Studies

Chapter 4. Guillain-Barre Syndrome (GBS) Diagnostics Market: Test Estimates & Trend Analysis

  • 4.1. Test Market Share, 2024 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Guillain-Barre Syndrome (GBS) Diagnostics Market by Product Test Outlook
  • 4.4. Lumbar Puncture
    • 4.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 4.5. Nerve Conduction Studies
    • 4.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 4.6. Electromyography
    • 4.6.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 4.7. Others
    • 4.7.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 5. Guillain-Barre Syndrome (GBS) Diagnostics Market: End Use Estimates & Trend Analysis

  • 5.1. End Use Market Share, 2024 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Guillain-Barre Syndrome (GBS) Diagnostics Market by End Use Outlook
  • 5.4. Hospitals and Clinics
    • 5.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 5.5. Diagnostic Laboratories
    • 5.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 5.6. Others
    • 5.6.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 6. Guillain-Barre Syndrome (GBS) Diagnostics Market: Regional Estimates & Trend Analysis, By Product, By Test, By End Use

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Global Regional Market Snapshot
  • 6.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.5. North America
    • 6.5.1. U.S.
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/ reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.2. Canada
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/ reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.3. Mexico
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework/ reimbursement structure
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Europe
    • 6.6.1. UK
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/ reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.2. Germany
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/ reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.3. France
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Regulatory framework/ reimbursement structure
      • 6.6.3.3. Competitive scenario
      • 6.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.4. Italy
      • 6.6.4.1. Key country dynamics
      • 6.6.4.2. Regulatory framework/ reimbursement structure
      • 6.6.4.3. Competitive scenario
      • 6.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.5. Spain
      • 6.6.5.1. Key country dynamics
      • 6.6.5.2. Regulatory framework/ reimbursement structure
      • 6.6.5.3. Competitive scenario
      • 6.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.6. Norway
      • 6.6.6.1. Key country dynamics
      • 6.6.6.2. Regulatory framework/ reimbursement structure
      • 6.6.6.3. Competitive scenario
      • 6.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.7. Sweden
      • 6.6.7.1. Key country dynamics
      • 6.6.7.2. Regulatory framework/ reimbursement structure
      • 6.6.7.3. Competitive scenario
      • 6.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.8. Denmark
      • 6.6.8.1. Key country dynamics
      • 6.6.8.2. Regulatory framework/ reimbursement structure
      • 6.6.8.3. Competitive scenario
      • 6.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. Asia Pacific
    • 6.7.1. Japan
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/ reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.2. China
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/ reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.3. India
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/ reimbursement structure
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.4. Australia
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/ reimbursement structure
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.5. South Korea
      • 6.7.5.1. Key country dynamics
      • 6.7.5.2. Regulatory framework/ reimbursement structure
      • 6.7.5.3. Competitive scenario
      • 6.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.6. Thailand
      • 6.7.6.1. Key country dynamics
      • 6.7.6.2. Regulatory framework/ reimbursement structure
      • 6.7.6.3. Competitive scenario
      • 6.7.6.4. Singapore market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8. Latin America
    • 6.8.1. Brazil
      • 6.8.1.1. Key country dynamics
      • 6.8.1.2. Regulatory framework/ reimbursement structure
      • 6.8.1.3. Competitive scenario
      • 6.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.8.2. Argentina
      • 6.8.2.1. Key country dynamics
      • 6.8.2.2. Regulatory framework/ reimbursement structure
      • 6.8.2.3. Competitive scenario
      • 6.8.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9. MEA
    • 6.9.1. South Africa
      • 6.9.1.1. Key country dynamics
      • 6.9.1.2. Regulatory framework/ reimbursement structure
      • 6.9.1.3. Competitive scenario
      • 6.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.2. Saudi Arabia
      • 6.9.2.1. Key country dynamics
      • 6.9.2.2. Regulatory framework/ reimbursement structure
      • 6.9.2.3. Competitive scenario
      • 6.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.3. UAE
      • 6.9.3.1. Key country dynamics
      • 6.9.3.2. Regulatory framework/ reimbursement structure
      • 6.9.3.3. Competitive scenario
      • 6.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.4. Kuwait
      • 6.9.4.1. Key country dynamics
      • 6.9.4.2. Regulatory framework/ reimbursement structure
      • 6.9.4.3. Competitive scenario
      • 6.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Key company market share/position analysis, 2024
  • 7.4. Company Profiles
    • 7.4.1. Cadwell Industries, Inc
      • 7.4.1.1. Company overview
      • 7.4.1.2. Financial performance
      • 7.4.1.3. Technology test benchmarking
      • 7.4.1.4. Strategic initiatives
    • 7.4.2. Natus Medical Incorporated
      • 7.4.2.1. Company overview
      • 7.4.2.2. Financial performance
      • 7.4.2.3. Technology test benchmarking
      • 7.4.2.4. Strategic initiatives
    • 7.4.3. Nihon Kohden Corporation
      • 7.4.3.1. Company overview
      • 7.4.3.2. Financial performance
      • 7.4.3.3. Technology test benchmarking
      • 7.4.3.4. Strategic initiatives
    • 7.4.4. Medtronic plc
      • 7.4.4.1. Company overview
      • 7.4.4.2. Financial performance
      • 7.4.4.3. Technology test benchmarking
      • 7.4.4.4. Strategic initiatives
    • 7.4.5. Bionen Medical Devices
      • 7.4.5.1. Company overview
      • 7.4.5.2. Financial performance
      • 7.4.5.3. Technology test benchmarking
      • 7.4.5.4. Strategic initiatives
    • 7.4.6. Deymed Diagnostic
      • 7.4.6.1. Company overview
      • 7.4.6.2. Financial performance
      • 7.4.6.3. Technology test benchmarking
      • 7.4.6.4. Strategic initiatives
    • 7.4.7. Neurosoft
      • 7.4.7.1. Company overview
      • 7.4.7.2. Financial performance
      • 7.4.7.3. Technology test benchmarking
      • 7.4.7.4. Strategic initiatives
    • 7.4.8. Alpine Biomed
      • 7.4.8.1. Company overview
      • 7.4.8.2. Financial performance
      • 7.4.8.3. Technology test benchmarking
      • 7.4.8.4. Strategic initiatives
    • 7.4.9. EMS Biomedical
      • 7.4.9.1. Company overview
      • 7.4.9.2. Financial performance
      • 7.4.9.3. Technology test benchmarking
      • 7.4.9.4. Strategic initiatives
    • 7.4.10. Rochester Electro-Medical, Inc
      • 7.4.10.1. Company overview
      • 7.4.10.2. Financial performance
      • 7.4.10.3. Technology test benchmarking
      • 7.4.10.4. Strategic initiatives
Show more
Product Code: GVR-4-68040-522-7

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 North America Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 4 North America Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 5 U.S. Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 6 U.S. Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 7 Canada Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 8 Canada Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 9 Mexico Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 10 Mexico Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 11 Europe Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 12 Europe Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 13 UK Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 14 UK Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 15 Germany Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 16 Germany Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 17 France Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 18 France Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 19 Italy Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 20 Italy Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 21 Spain Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 22 Spain Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 23 Denmark Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 24 Denmark Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 25 Sweden Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 26 Sweden Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 27 Norway Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 28 Norway Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 31 Japan Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 32 Japan Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 33 China Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 34 China Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 35 India Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 36 India Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 37 Australia Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 38 Australia Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 39 South Korea Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 40 South Korea Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 41 Thailand Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 42 Thailand Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 43 Latin America Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 44 Latin America Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 45 Brazil Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 46 Brazil Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 47 Argentina Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 48 Argentina Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 49 MEA Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 50 MEA Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 51 South Africa Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 52 South Africa Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 53 Saudi Arabia Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 54 Saudi Arabia Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 55 UAE Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 56 UAE Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 57 Kuwait Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 58 Kuwait Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Guillain-Barre Syndrome (GBS) Diagnostics market outlook
  • Fig. 9 Guillain-Barre Syndrome (GBS) Diagnostics competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Guillain-Barre Syndrome (GBS) Diagnostics market driver impact
  • Fig. 15 Guillain-Barre Syndrome (GBS) Diagnostics market restraint impact
  • Fig. 16 Guillain-Barre Syndrome (GBS) Diagnostics market strategic initiatives analysis
  • Fig. 17 Guillain-Barre Syndrome (GBS) Diagnostics market: Test analysis
  • Fig. 18 Guillain-Barre Syndrome (GBS) Diagnostics market: Test outlook and key takeaways
  • Fig. 19 Clinical writing market estimates and forecast, 2018 - 2030
  • Fig. 20 Lumbar puncture market estimates and forecast, 2018 - 2030
  • Fig. 21 Nerve conduction studies market estimates and forecast, 2018 - 2030
  • Fig. 22 Electromyography market estimates and forecast, 2018 - 2030
  • Fig. 23 Others market estimates and forecast, 2018 - 2030
  • Fig. 24 Guillain-Barre Syndrome (GBS) Diagnostics market: End use movement analysis
  • Fig. 25 Guillain-Barre Syndrome (GBS) Diagnostics market: End use outlook and key takeaways
  • Fig. 26 Hospitals and clinics market estimates and forecast, 2018 - 2030
  • Fig. 27 Diagnostic laboratories market estimates and forecast, 2018 - 2030
  • Fig. 28 Global Guillain-Barre Syndrome (GBS) Diagnostics market: Regional movement analysis
  • Fig. 29 Global Guillain-Barre Syndrome (GBS) Diagnostics market: Regional outlook and key takeaways
  • Fig. 30 Global Guillain-Barre Syndrome (GBS) Diagnostics market share and leading players
  • Fig. 31 North America market share and leading players
  • Fig. 32 Europe market share and leading players
  • Fig. 33 Asia Pacific market share and leading players
  • Fig. 34 Latin America market share and leading players
  • Fig. 35 Middle East & Africa market share and leading players
  • Fig. 36 North America: SWOT
  • Fig. 37 Europe SWOT
  • Fig. 38 Asia Pacific SWOT
  • Fig. 39 Latin America SWOT
  • Fig. 40 MEA SWOT
  • Fig. 41 North America market estimates and forecasts, 2018 - 2030
  • Fig. 42 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 43 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 44 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 45 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 46 UK market estimates and forecasts, 2018 - 2030
  • Fig. 47 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 48 France market estimates and forecasts, 2018 - 2030
  • Fig. 49 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 50 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 51 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 52 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 53 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 54 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 55 China market estimates and forecasts, 2018 - 2030
  • Fig. 56 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 57 India market estimates and forecasts, 2018 - 2030
  • Fig. 58 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 59 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 60 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 61 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 62 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 63 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 64 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 65 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 66 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 67 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 68 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 69 Market share of key market players- Guillain-Barre Syndrome (GBS) Diagnostics market
  • Fig. 70 Key Company Categorization
  • Fig. 71 Company Market Share/Position Analysis, 2024
  • Fig. 72 Strategic Framework
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!